A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2016-05-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 28
- Registration Number
- NCT01863784
A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2013-05-24
- Last Posted Date
- 2015-07-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 21
- Registration Number
- NCT01862224
Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1820
- Registration Number
- NCT01856309
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Phase 3
Completed
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 838
- Registration Number
- NCT01855750
A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1
Terminated
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2013-05-14
- Last Posted Date
- 2019-06-17
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 17
- Registration Number
- NCT01853228
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 3
Completed
- Conditions
- Fallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal Neoplasms
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2019-04-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 581
- Registration Number
- NCT01846611
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-42721458 (single dose)Drug: Placebo (single dose)Drug: JNJ-42721458 (multiple doses)Drug: Placebo (multiple doses)
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT01840501
A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Neoplasms
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2018-11-07
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT01834209
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2014-11-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT01827982
The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 43
- Registration Number
- NCT01826786
© Copyright 2025. All Rights Reserved by MedPath